Clinical Trial Update: Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating EGEN-001 in combination with carboplatin and docetaxel in recurrent platinum-sensitive ovarian cancer to assess safety and preliminary …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)
• EGEN-001

Snippet

Sponsor: EGEN, Inc. | Conditions: Ovarian Neoplasms | Phase 1 | Status: COMPLETED